Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;20(3):488-496.
doi: 10.1111/dom.13132. Epub 2017 Nov 22.

Identification of barriers to insulin therapy and approaches to overcoming them

David Russell-Jones  1 , Frans Pouwer  2 , Kamlesh Khunti  3
Affiliations
Review

Identification of barriers to insulin therapy and approaches to overcoming them

David Russell-Jones et al. Diabetes Obes Metab. 2018 Mar.

Abstract

Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability of numerous glucose-lowering therapies and clear guidelines for T2D management. Tackling clinical or therapeutic inertia, where the person with diabetes and/or their healthcare providers do not intensify treatment regimens despite this being appropriate, is key to improving patients' long-term outcomes. This gap between best practice and current level of care is most pronounced when considering insulin regimens, with studies showing that insulin initiation/intensification is frequently and inappropriately delayed for several years. Patient- and physician-related factors both contribute to this resistance at the stages of insulin initiation, titration and intensification, impeding achievement of optimal glycaemic control. The present review evaluates the evidence and reasons for this delay, together with available methods for facilitation of insulin initiation or intensification.

Keywords: insulin therapy; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

D. R. J. reports having received research funds from AstraZeneca, Sanofi‐Aventis, Novo Nordisk, Janssen, Takeda, Boehringer Ingelheim, and speaker honoraria from AstraZeneca, Sanofi‐Aventis, Lilly, Novo Nordisk, Janssen, Takeda and Boehringer Ingelheim, and has been a consultant, board member or member of advisory panels for AstraZeneca, Sanofi‐Aventis, Lilly and Novo Nordisk. F. P. has received research support from Novo Nordisk to analyse data from the DAWN2 study. K. K. reports having received speaker honoraria from Novartis, Novo Nordisk, Sanofi‐Aventis, Lilly, Merck Sharp & Dohme, Janssen, AstraZeneca and Boehringer Ingelheim, and having received research support from Novartis, Novo Nordisk, Sanofi‐Aventis, Lilly, Pfizer, Boehringer Ingelheim, Merck Sharp & Dohme, Janssen and Roche, and being a consultant for Novartis, Novo Nordisk, Sanofi‐Aventis, Lilly, Merck Sharp & Dohme, Janssen, AstraZeneca and Boehringer Ingelheim, and being a member of advisory panels for Lilly, Sanofi‐Aventis, Merck Sharp & Dohme, Novo Nordisk, Boehringer Ingelheim, Janssen, BMS, AstraZeneca, Amgen and Servier.

Figures

Figure 1
Figure 1
Barriers and solutions to therapeutic inertia. Floating spheres can be considered as a general solution to all named barriers
See this image and copyright information in PMC

References

    1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. - PMC - PubMed
    1. Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540–2553. - PubMed
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10‐year follow‐up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. - PubMed
    1. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta‐analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772. - PubMed
    1. Khunti K, Millar‐Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11(1):3–12. - PubMed

Publication types

MeSH terms